TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF), a commercial-stage healthcare company focused on pain, inflammation and regenerative medicine, is pleased to announce the signing of an exclusive Licensing and Distribution Agreement with Induce Biologics Inc. (“Induce”) for the Canadian rights for Induce’s URIST™ biological product for dental and craniofacial applications. URIST™ is a novel bone graft substitute that contains bone morphogenetic protein-2 (BMP), and is being developed as a means of promoting the regeneration of bone following dental and oral maxillofacial surgery. Animal studies have demonstrated the ability of URIST™ to potently stimulate bone re-growth. Orthobiologics (the use of biological approaches to regenerate and repair bone) is estimated to be a US$4.4 billion market. BMP-based products are among the largest segments of this market.
